Search results for "EVENTS"

showing 10 items of 514 documents

Search for diphoton events with large missing transverse energy in 7 TeV proton-proton collisions with the ATLAS detector.

2011

A search for diphoton events with large missing transverse energy is presented. The data were collected with the ATLAS detector in proton-proton collisions at √s=7  TeV at the CERN Large Hadron Collider and correspond to an integrated luminosity of 3.1  pb−1. No excess of such events is observed above the standard model background prediction. In the context of a specific model with one universal extra dimension with compactification radius R and gravity-induced decays, values of 1/R<729  GeV are excluded at 95% C. L., providing the most sensitive limit on this model to date.

Particle physicsMISSING TRANSVERSE ENERGYCiências Naturais::Ciências FísicasAtlas detector:Ciências Físicas [Ciências Naturais]FIS/04 - Fisica Nucleare e SubnucleareGeneral Physics and AstronomyFOS: Physical sciencestransverse energy: missing-energy ; ATLAS ; universal extra dimension ; compactification ; CERN LHC Coll ; background ; p p: interaction ; final state: two-photon ; photon: Kaluza-Klein ; electroweak interaction: standard model: validity test ; experimental results ; 7000 GeV-cmsddc:500.201 natural sciences7. Clean energy530High Energy Physics - ExperimentNuclear physicsUniversal extra dimensionHigh Energy Physics - Experiment (hep-ex)0103 physical sciencesddc:550[PHYS.HEXP]Physics [physics]/High Energy Physics - Experiment [hep-ex]diphoton; events; transverse energy;proton-proton collisions; Hadron;ddc:530High Energy PhysicsSpecific model010306 general physicsNuclear ExperimentGeneralLiterature_REFERENCE(e.g.dictionariesencyclopediasglossaries)QCPhysicsLarge Hadron ColliderScience & TechnologyCompactification (physics)010308 nuclear & particles physicsAtlas (topology)Settore FIS/01 - Fisica SperimentaleFísicaFIS/01 - Fisica SperimentaleATLASTransverse planeCol·lisions (Física nuclear)Experimental High Energy PhysicsUniversal Extra DimensionsFísica nuclearHigh Energy Physics::ExperimentLHCParticle Physics - ExperimentPhysical review letters
researchProduct

Search for diphoton events with large missing transverse momentum in 7 TeV proton-proton collision data with the ATLAS detector

2012

A search for diphoton events with large missing transverse momentum has been performed using proton–proton collision data at √s = 7 TeV recorded with the ATLAS detector, corresponding to an integrated luminosity of 4.8 fb[superscript −1]. No excess of events was observed above the Standard Model prediction and model-dependent 95% confidence level exclusion limits are set. In the context of a generalised model of gauge-mediated supersymmetry breaking with a bino-like lightest neutralino of mass above 50 GeV, gluinos (squarks) below 1.07 TeV (0.87 TeV) are excluded, while a breaking scale Λ below 196 TeV is excluded for a minimal model of gauge-mediated supersymmetry breaking. For a specific …

ParticleLambda01 natural sciencesHigh Energy Physics - ExperimentUniversal extra dimensionHigh Energy Physics - Experiment (hep-ex)proton-proton collisionExtensionBibliography[PHYS.HEXP]Physics [physics]/High Energy Physics - Experiment [hep-ex]QCPhysicsLarge Hadron ColliderSettore FIS/01 - Fisica SperimentaleSupersymmetry breakingDynamical Supersymmetry BreakingComputingMethodologies_DOCUMENTANDTEXTPROCESSINGdiphoton events; ATLAS detectorUniversal Extra DimensionsPhenomenologyFísica nuclearPhenomenology (particle physics)Particle Physics - ExperimentParticle physicsNuclear and High Energy PhysicsFortran CodeCiências Naturais::Ciências FísicasAstrophysics::High Energy Astrophysical PhenomenaSupergauge Transformations:Ciências Físicas [Ciências Naturais]FOS: Physical sciencesddc:500.2530Partícules (Física nuclear)Nuclear physicsMinimal model0103 physical sciencesddc:530010306 general physicsCiencias ExactasScience & TechnologyATLAS detector010308 nuclear & particles physicsHigh Energy Physics::PhenomenologyFísicadiphotonHadron CollidersGeneratorsHADRON-HADRON COLLISIONSNeutralinoExperimental High Energy PhysicsHigh Energy Physics::ExperimentModel
researchProduct

Risk assessment in ginecology and obstetrics in Sicily: an approach based on Wolff's Criteria

2013

Objectives To apply Wolff’s Criteria to hospital discharge records (HDR) in order to detect adverse events worthy of further study. Methods Gynecology and Obstetrics Units of three Sicilian hospitals were considered and HDR regarding ordinary and day hospital admissions in 2008 were collected. A matched case-control study was designed, by random selection of 10 controls at maximum for each case. Matching was performed on the variables age and speciality of admission (gynecology or obstetrics). Results Out of a total of 7011 HDR examined, 114 cases were identified with Wolff’s Criteria. Multivariate analysis confirmed a statistically significant association with the origin of admission, diag…

Patient TransferReoperationGenital Neoplasms FemaleSettore MED/42 - Igiene Generale E ApplicataPatient ReadmissionRisk AssessmentSettore MED/01 - Statistica MedicaGynecologic Surgical ProceduresPregnancyRisk FactorsAmbulatory CarePrevalenceHumansHospital MortalityObstetrics and Gynecology Department HospitalRisk ManagementLength of StayDelivery ObstetricQuality ImprovementPatient DischargeIntensive Care UnitsItalyCase-Control StudiesWolff’s Criteria Adverse Events Clinical Risk Obstetrics GynecologyFemalePatient SafetyEmergencies
researchProduct

Impact of universal vaccination against varicella in Italy: Experiences from eight Italian Regions.

2014

In Italy, the introduction of Universal Varicella Vaccination (UVV) has been decided but postponed, as a national programme, until 2015, when data from Regions which have already implemented it will be available. Starting from 2003, eight Italian Regions (Basilicata, Calabria, Friuli Venezia Giulia, Apulia, Sardinia, Sicily, Tuscany and Veneto) have progressively introduced UVV, in their immunization programme, with different schedules in children aged 13-15 months and 5-6 years, currently a two-dose schedule is adopted by all Regions. In June 2013, an Interregional Group on Varicella Vaccination (IGVV) has been established in order to assess the effectiveness of varicella vaccination with …

Pediatricsmedicine.medical_specialtyImmunologyadverse events following varicella immunizationVaricellaSettore MED/42 - Igiene Generale E ApplicataEnvironmental healthmedicineImmunology and AllergyHealth policyChickenpox VaccinePharmacologyChickenpoxbusiness.industryIncidence (epidemiology)immunization coverageHealth services researchUniversal Varicella VaccinationnotificationsVaricella; Universal Varicella Vaccination; Notifications; Hospitalizations; Immunization coverage; Adverse effectsmedicine.diseaseVaccinationImmunizationVaccination coverageUniversal Varicella Vaccination; Varicella; adverse events following varicella immunization; hospitalizations; immunization coverage; notificationsbusinesshospitalization
researchProduct

Data of safety in a single-center alemtuzumab treated population

2020

Alemtuzumab is approved for highly active MS and, in Europe, can be employed after other disease-modifying treatments (DMTs) as an escalation approach or first therapeutic option. The occurrence of secondary autoimmune adverse events and infections differs depending on the employed approach.In the manuscript entitled “Alemtuzumab treatment of multiple sclerosis in real-world clinical practice: report from a single Italian center” by di Ioia M. and collaborators, efficacy and safety data of alemtuzumab were evaluated in a real-world MS population. The aim of the article is to describe in detail the unexpected serious adverse events which occurred in this cohort during and after the administr…

Pediatricsmedicine.medical_specialtyPopulationlcsh:Computer applications to medicine. Medical informaticsSingle CenterMultiple sclerosis03 medical and health sciences0302 clinical medicinemedicinelcsh:Science (General)Adverse effecteducationAutoimmune hemolytic anemiaAlemtuzumabSecondary autoimmune disorders030304 developmental biology0303 health scienceseducation.field_of_studyMultidisciplinarybusiness.industryMultiple sclerosismedicine.diseasePancytopeniaAdverse eventsCohortlcsh:R858-859.7AlemtuzumabSettore MED/26 - NeurologiaAutoimmune hemolytic anemiaSafetybusiness030217 neurology & neurosurgerylcsh:Q1-390medicine.drugNeuroscience
researchProduct

Adverse Events in Treatment of Inherited Factor VII Deficiency: Final Analysis of the STER

2012

Abstract Abstract 2279 Introduction No evidence-based guidelines are available for the treatment of Factor VII deficiency. Replacement therapy (RT) is still influenced by different factors as rarity of the disorder, availability and supply of products and economic reasons. All RTs are not exempt of side effects and scanty data is available about the safety of the products currently used. Aim of this study was to analyze adverse events (AEs) of RTs for congenital Factor VII deficiency, as reported in Seven Treatment Evaluation Registry (STER). Design and Methods FVII deficiency patients treated for bleeding episodes, prophylaxis, and surgery were investigated for RT-related AEs over a period…

Pediatricsmedicine.medical_specialtySuperficial vein thrombosisFactor VIIbusiness.industryImmunologyAdverse Events Inherited Fasctor VII deficiencyCell BiologyHematologymedicine.diseaseBiochemistryThrombosisProthrombin complex concentratechemistry.chemical_compoundchemistryMedicineObservational studyFresh frozen plasmabusinessFactor VII deficiencyAdverse effectmedicine.drug
researchProduct

Statins and new-onset diabetes

2013

Statins are highly efficacious lipid modifying agents that reduce the risk for cardiovascular (CV) events in both primary and secondary prevention settings. However, statins affect molecular mechanisms which adversely impact on insulin sensitivity and β-cell function, thereby increasing risk for new onset diabetes mellitus (NOD). Defining the mechanisms involved is the focus of considerable current investigation. The statins reduce the risk for CV events in normoglycemic patients as well as in those with diabetes mellitus (DM) and their benefits outweigh the risk of inducing NOD. We review the clinical evidence for NOD with statin treatment, as well as the potential mechanisms involved. Our…

PharmacologySecondary preventionLIPID MODIFYING AGENTSbusiness.industrynutritional and metabolic diseasesInsulin sensitivityNodPharmacologyStatin treatmentBioinformaticsmedicine.diseaseRisk AssessmentPrimary PreventionDiabetes Mellitus Type 2New onset diabetesCardiovascular DiseasesDiabetes mellitusDrug DiscoverySecondary PreventionmedicineHumansHydroxymethylglutaryl-CoA Reductase InhibitorsRisk assessmentbusinessnew-onset diabetes mellitus statin cardiovascular events insulin sensitivity primary prevention secondary prevention
researchProduct

Adverse events as potential predictive factors of activity in patients with advanced hepatocellular carcinoma treated with lenvatinib

2021

Background and Aim: Lenvatinib is a standard of care option in first-line therapy of advanced hepatocellular carcinoma (HCC). In the present study, we aim to identify, in patients with HCC treated with lenvatinib, a possible association between occurrence and grading of adverse events (AEs) and outcome. Methods: We performed a retrospective analysis of 606 Japanese and Italian patients treated with lenvatinib in first-line setting and investigated the possible correlation between the onset of AEs, toxicity grade (G) and outcome measures such as overall survival (OS) and progression-free survival (PFS). Results: The appearance of arterial hypertension G ≥ 2 independently predicted prolonged …

Phenylurea Compoundmedicine.medical_specialtyCarcinoma HepatocellularMultivariate analysispredictive factorsadverse eventlenvatinibGastroenterologypredictive factorchemistry.chemical_compoundQuality of lifeInternal medicinemedicineHumansAdverse effectRetrospective Studiesadverse events; hepatocellular carcinoma; lenvatinib; predictive factorsSettore MED/12 - GastroenterologiaHepatologybusiness.industryPhenylurea CompoundsLiver NeoplasmsHazard ratiohepatocellular carcinomamedicine.diseaseadverse eventsConfidence intervalDiscontinuationchemistryLiver NeoplasmHepatocellular carcinomaQuality of LifeQuinolinesLenvatinibbusiness
researchProduct

Search for Diphoton Events with Large Missing Transverse Energy with 36 pb^-1 of 7 TeV Proton-Proton Collision Data with the ATLAS Detector

2011

Making use of 36 pb^-1 of proton-proton collision data at sqrt{s} = 7 TeV, the ATLAS Collaboration has performed a search for diphoton events with large missing transverse energy. Observing no excess of events above the Standard Model prediction, a 95% Confidence Level (CL) upper limit is set on the cross section for new physics of sigma &lt; 0.38 - 0.65 pb in the context of a generalised model of gauge mediated supersymmetry breaking (GGM) with a bino-like lightest neutralino, and of sigma &lt; 0.18 - 0.23 pb in the context of a specific model with one universal extra dimension (UED). A 95 % CL lower limit of 560 GeV, for bino masses above 50 GeV, is set on the GGM gluino mass, while a low…

Physics and Astronomy (miscellaneous)Physics beyond the Standard ModelParticleProton–proton collision01 natural sciencesHigh Energy Physics - ExperimentUniversal extra dimensionHigh Energy Physics - Experiment (hep-ex)Diphoton eventsExtension[PHYS.HEXP]Physics [physics]/High Energy Physics - Experiment [hep-ex]Nuclear ExperimentPhysicsCompactification (physics)Settore FIS/01 - Fisica SperimentaleSigmaSupersymmetryATLASTransverse planePhysical SciencesDynamical Supersymmetry BreakingUniversal Extra DimensionsFísica nuclearPhenomenologyLHCPhenomenology (particle physics)Particle Physics - ExperimentParticle physicsFortran CodeSupergauge TransformationsFOS: Physical sciencesproton–proton collision; ATLAS detectorddc:500.25300103 physical sciencesFysikddc:530High Energy Physics010306 general physicsEngineering (miscellaneous)Ciencias Exactas010308 nuclear & particles physicsFísicaCollisionHadron CollidersGeneratorsCol·lisions (Física nuclear)High Energy Physics::ExperimentSupersymmetryModel
researchProduct

Quantification of Competing Magnetic States and Switching Pathways in Curved Nanowires by Direct Dynamic Imaging.

2020

For viable applications, spintronic devices based, for example, on domain wall motion need to be highly reliable with stable magnetization states and highly reproducible switching pathways transforming one state to another. The existence of multiple stable states and switching pathways in a system is a definitive barrier for device operation, yet rare and stochastic events are difficult to detect and understand. We demonstrate an approach to quantify competing magnetic states and stochastic switching pathways based on time-resolved scanning electron microscopy with polarization analysis, applied to the technologically relevant control of vortex domain wall chirality via field and curvature …

PhysicsMagnetizationSpintronicsChemical physicsDynamic imagingGeneral EngineeringRare eventsNanowireGeneral Physics and AstronomyGeneral Materials SciencePolarization (waves)CurvatureVortexACS nano
researchProduct